Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland (HepCOP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00473993|
Recruitment Status : Completed
First Posted : May 16, 2007
Last Update Posted : February 16, 2009
Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine. While stabilized by an opioid maintenance treatment (OMT)chronic hepatitis C can be treated with pegylated interferon plus ribavirin. As not sufficiently known, the results are comparable to the results of the treatment of nonaddicts.
Our crossectional study investigates how many patients undergoing OMT are adequately investigated concerning hepatitis C. If not, why are they not adequately investigated and treated? Representative data are collected in the local clinics and medical practices involved in OMT in the Kanton of Zurich. The patients files are revised and the involved doctors are asked through a structured interview.
|Condition or disease|
|Hepatitis C, Chronic Substance Abuse Treatment Centers Opioid-Related Disorders|
|Study Type :||Observational|
|Official Title:||Hepatitis C Bei Opioidabhängigen in Der Praxis, Eine Querschnittsuntersuchung|
|Study Start Date :||July 2007|
|Actual Study Completion Date :||December 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00473993
|Study Director:||André Seidenberg, Dr.med.||research fellow EHAM, University of Zurich|